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Abstract 
Platinum complexes have been used for anti-cancer propose for decades, however, their high side 
effects resulting from damage to healthy cells cannot be neglected and prevent further clinical 
utilisation. Here, we designed a cyclometalated platinum (II) complex that can bind the endogenous 
nuclear factor-κB (NF-κB) protein. Employing detailed colocalization studies in co-culture cell line 
models, we show that by binding to NF-κB, the platinum (II) complex is capable of upregulated 
nuclear translocation specifically in cancer but not normal cells, thereby impairing cancer 
proliferation without disturbing healthy cells. In a murine tumour model, the platinum (II) complex 
prevents tumour growth to a greater extent than cisplatin and with considerably lower side-effects 
and kidney damage. Considering its weak damage to normal cells combined with high toxicity to 
cancer cells, this NF-κB-binding platinum complex is a potential anti-cancer candidate and acts to 
verify the strategy of hijacking endogenous trans-nuclear proteins to achieve cancer-cell specificity 
and enhance therapeutic indices. 
Key words: Theranostic; Platinum complex; Nuclear factor kappa B; Cancer therapy 
Introduction 
Platinum complexes have attracted sufficient 
attention as anti-tumour agents and thousands of 
platinum complexes have been synthesized and 
screened as potential anticancer candidates [1-3]. 
However, despite the fact a few platinum agents (e.g. 
cisplatin, carboplatin and oxalipatin) are extremely 
successful in clinical applications [4,5], ‘fresh blood’ in 
metallo-drug design is required to overcome 
drawbacks of these classical agents and broaden the 
range of treatable tumours [6,7]. As a significant 
defect, classical platinum drugs have a small 
therapeutic index and barely discriminate between 
cancer and healthy cells. Other factors that restricted 
their use are systemic toxicity and the almost 
inevitable drug resistance [8-11]. Researchers have 
found that functionalized nanoparticles could favour 
platinum complexes to deliver in place, as well as 
avoiding side-effect to certain degree [12-15]. Despite 
the efforts made in manufacturing artificial vectors for 
delivery, small and smart platinum molecular system 
(Mw < 1000) still remain advantageous, yet increasing 
the activity of platinum complexes in cancer cells 
whilst leaving normal cells unaffected would clearly 
be beneficial.  
Endogenous trans-nuclear proteins represent 
one such potential target. There are several 
transcription factors periodically relocating between 
the cytosol and nucleus during inflammations 
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including cancer [16-18]. Among them, nuclear 
factor-κB (NF-κB), a key mediator of inducible 
transcription in the immune systems, plays a critical 
role in immunology and cancer biology [19-23]. Five 
NF-κB subunits have been described: p50 (NF-κB1), 
p52 (NF-κB2), p55 (Rel A), p65 (Rel B), and c-Rel (Rel) 
[24]. It is known that in resting cells, NF-κB is inactive, 
residing predominantly in the cytosol where it is 
bound to IκB inhibitory proteins [19-22]. On the 
contrary, in cells infracted by inflammation and the 
genetic onset of cancer, NF-κB is activated through 
subsequent polyubiquitylation and proteasomal 
degradation, allowing NF-κB to translocate to the 
nucleus where it drives the expression of the genes 
associated with cell proliferation, angiogenesis, 
metastasis, tumor promotion, inflammation and 
suppression of apoptosis to affect/control the 
inflammation and cancer [25-28]. NF-κB intracellular 
trafficking therefore offers an elegant possibility to 
hijack it as an endogenous vector to deliver agents to 
the nucleus of cancer cells, discriminately and 
significantly impacting cancer cells whilst sparing 
healthy tissue. 
In addition to cisplatin and its derivatives, the 
study of neutral platinum complexes with 
cyclometalated 2,6-diphenylpyridine ligand 
(C^N^C-H2) has been an area of considerable interest 
[29] and numerous pincer platinum complexes with 
anti-cancer properties have been described [12,30]. 
Notably, this includes work showing tridentate 
2,6-diphenylpyridine square planar platinum 
complexes are able to inhibit NF-κB-dependent gene 
transcription [31]. Advantages of cyclometalated Pt 
complexes for bio-applications include the fact many 
are neutral molecules and so will not influence the 
extracellular/intracellular charge balance [32] while 
certain complexes emit from long-lived 
metal-to-ligand or ligand-to-ligand charge transfer 
states, providing a convenient method to track 
intracellular localization using fluorescence 
microscopy [33]. 
Here, we present the synthesis and biological 
activity of the cyclometalated Pt complex, 
[Pt(DMSO)(2,4,6-triphenylpyridine)]. This Pt complex 
consists of a planar cyclometalated tridentate ligand, 
2,4,6-triphenylpyridine, where the two Pt-C bonds 
resulting a high persistent in extra-dilute solution and 
biotic environment than traditional Pt complexes with 
less heavy metal toxicity. The remaining coordination 
site is occupied by dimethyl sulfoxide, a ligand that 
could maintain the molecular stability in aqueous 
solution as well as be substituted by a stronger 
coordinating bio-species. We find that this Pt complex 
is able to bind NF-κB protein and shows strong 
co-localisation with NF-κB in cell co-staining 
experiments. Interestingly, in cancer cells, the 
platinum-bound active NF-κB protein complex was 
transported to the cell nucleus, which led to a high 
rate of apoptosis. In normal cells, however, the 
platinum complex remained in the cytosolic region of 
cells with minor cytotoxicity. The finding that an 
emissive Pt complex may distinguish normal cells and 
cancer cell by hijacking NF-κB protein not only 
exploits a new concept in the design of 
next-generation platinum drugs but also inspires the 
development of new therapeutics based on hijacking 
endogenous transcription factors. 
Results and Discussion 
Design and synthesis 
We synthesized [Pt(DMSO)(2,4,6-triphenyl-
pyridine)] (referred to as “Pt complex” hereafter) in a 
mild and straightforward method according to a 
mechanism described in the literature (Figure 1A-B 
and Scheme S1) [29]. After purification, the molecular 
structure of Pt complex was confirmed by 1H NMR, 
13C NMR, 195Pt NMR, MALDI-TOF-MS spectra and 
crystal structural analysis (Figure S1-S3, Table S1-S2). 
We conducted molecular modelling calculation 
to examine the binding ability between Pt complex 
and NF-κB protein by using Discovery Studio 4.1. For 
inactive NF-κB protein, the Pt complex inlays the 
cavity consisted by three polypeptides (p50, p60, iκB) 
and van der Waals interaction could be observed 
between Pt complex and inactive NF-κB protein with 
maximum binding energy -37.5294 Kcal/mol, (Figure 
1C-D and Table S3). For active NF-κB protein, the 
primary interactions were ionic electrostatic action 
and hydrogen bonding which were generated 
between Pt complex and p50 polypeptides with 
maximum binding energy -30.5267 Kcal/mol, (Figure 
S4, Table S3). Considering the maximum binding 
energy, Pt complex was easier to separate from the 
active NF-κB protein than the inactive protein.  
Photophysical properties 
The absorption spectrum of Pt complex showed 
peak maxima at ~275 nm, ~350 nm and a broad 
absorption appearing at 375-550 nm (Figure S5). There 
is a small solvatochromic shift (~ 5 nm) upon 
changing the solvent from dichloromethane to 
acetonitrile. Due to non-radiative processes 
concerning low-lying d-d excited states and fast 
non-radiative decay rate, Pt complex was 
non-emissive in fluid solutions at room temperature. 
However, Pt complex displayed vibronically 
structured emission as a glassy solution in 2-MeTHF 
at 77K (Figure S6). 
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Figure 1. The molecular (A) and single-crystal (B, H atoms and solvent molecules were omitted for clarity) structure of Pt complex. (C) 2D, (D) 3D, (E) van der Waals 
interactions of Pt complex and inactive NF-κB protein by molecular modelling calculation. 
 
Visualizations of Pt complex in cells 
According to the literature, certain cyclometa-
lated Pt complexes display non-emission/weak 
emission in aqueous solutions, however, when 
combined with macromolecules, such as protein, 
DNA etc., distinct activation of emission or emission 
enhancement could be observed [34,35]. This is the 
result of hydrophobic interactions, which restrict the 
vibrations of platinum complexes, and the shielding 
of platinum complexes from O2 by the 
macromolecules.  
We therefore attempted to evaluate the 
intracellular distribution of Pt complex in normal cells 
and cancer cells under confocal imaging. Firstly, five 
types of normal cells including HELF (Human 
embryo liver fibroblast), Astrocyte (mouse), bEND3 
(mouse brain endothelium), 293T (Human embryonic 
kidney cells), and NIH 3T3 cells (mouse embryo 
fibroblast) were selected to incubate with 10 µM Pt 
complex for 30 min (Figure 2(A)). The micro-graphs 
along with a magnified region that indicated single 
cell clearly displayed the fluorescent signals with 
good photon-stability in cytosolic space but highly 
excluded from the nuclear region (Figure S7 and 2A). 
This is further confirmed via analysis of normalised 
fluorescence intensity, in which the cytosolic emission 
was much greater than that in the nucleus (Figure 2A, 
bar graphs). Strikingly, and in stark contrast to the 
results for normal cell lines, all nine evaluated cancer 
cell lines incubated with Pt complex (HepG2, 
HSS5787, Hela, MCF-7, H460, SHSY5Y, 
MDA-MB-231, A549, and U2O3 cells) displayed 
strong emission from the nucleus (Figure 2B). In 
contrast, the cytosolic fluorescence indicated 
relatively weaker internalisation in this cellular region 
(e.g. HepG2 and H460 cells). Along with the high 
stability of Pt complex in cell culture media (Figure 
S8), these results are consistent with the observed 
emission to be the result of the interaction of the Pt 
complex with a cellular protein.  
To further understand the differential 
subcellular distribution between normal and cancer 
cells, the murine macrophage cell line RAW264.7 cells 
were chosen as a healthy/inflammatory cell model. It 
is known that macrophages as an immunocyte are 
rich in NF-κB protein with an inactive form within the 
cytosol, yet by external stimulations (e.g. 
lipopolysaccharide, LPS), RAW264.7 cells undergo 
inflammation and the NF-κB protein is activated and 
shuttled between nucleus and cytosol [16]. As shown 
in Figure 2(C), the emission signal of Pt complex is 
principally within the cytosol in inactive RAW264.7 
cells; consistent with previous results employing 
normal cells. Interestingly, when cells were 
stimulated with LPS, the Pt complex displayed clear 
fluorescent emission in the nucleus.  
Transmission electron microscopy (TEM) and 
ICP-MS analysis 
Platinum complexes with high electron density 
are ideal for scattering the electron beam used in 
transmission electron microscopy and this method 
may provide information on their intracellular 
distribution [36]. Accordingly, Pt complex-treated 
HELF and HepG2 cells (representatives for normal 
and cancer cells, respectively) were processed for 
TEM imaging. A classic membrane-localizing contrast 
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agent osmium tetroxide (OsO4) was introduced as a 
control. It is shown in Figure 3A-C that HELF and 
HepG2 stained solely with OsO4 displayed clear 
contrast in subcellular membrane including 
mitochondria and nuclear membrane structures. 
Visualizing Pt complex–treated cells with no other 
contrast agent applied after TEM preparation did not 
provide any membrane signal, but significant 
accumulation in the nuclear region in cancer cells was 
apparent. In contrast, negligible signal in the nucleus 
of normal cells was observed. In a parallel experiment 
under similar treatment, inductively coupled plasma 
mass spectrometry (ICP-MS) was used to quantify the 
platinum content in isolated cytosol and nuclear 
fractions of Pt complex–treated cells (Figure 3(D)). 
ICP-MS indicated that platinum content was 0.19 ± 
0.02 µg/L in the nucleus and 4.47 ± 0.22 µg/L in the 
cytosol for normal HELF cells. On the contrary, the 
content was 4.98 ± 0.24 µg/L in the nucleus and 0.012 
± 0.01 µg/L in the cytosol for cancer HepG2 cells. The 
normalized platinum substances in each cell also 
indicated the same distribution pattern (Figure 3E). 
However, compared with Pt complex, the ICP-MS 
data of cisplatin (Table S4) showed no obvious 
organelles distribution difference in normal and 
cancer cells.  
Co-localization with NF-κB protein by 
immunofluorescence method 
The above experiments strongly suggested that 
the synthetic Pt complex displayed distinct 
intracellular distribution properties in normal 
compared to cancer cells and we speculated that this 
might be due to the hijacking of NF-κB protein by Pt 
complex. To explore this further, immunofluorescence 
was applied to determine cellular NF-κB localisation. 
Figure 4 shows the strong co-localization of Pt 
complex with NFκB (2nd ab: Cy3, λex = 550 nm, λem = 
560-600 nm) in HepG2 cells, strongly implying that 
the Pt complex signal corresponds to NF-κB protein 
(Rr = 0.828). Importantly, LPS induced NF-κB protein 
translocation using the RAW264.7 inflammation cell 
line model confirmed that the transport of Pt complex 
in cells is NF-κB protein dependent, with positive 
 
 
Figure 2. Confocal imaging of normal cells (A) and cancer cells (B) incubated with Pt complex (10 µM, 1 h, λex = 405 nm, λem = 480-520 nm). The column picture in (A) and (B) 
was the emission intensity analysis (average per area) from the nuclear and cytosolic region, respectively. (C) The LPS inactive/active RAW264.7 cells treated with Pt complex 
(10 µM, 1 h). Scale bars = 10 μm, data point = 30 cells, Error bar SEM, p < 0.005. 
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Pearson coefficients of 0.754 and 0.683 for the LPS free 
and LPS treated group, respectively. In addition to 
these cellular experiments, protein electrophoresis 
analysis and fluorescence emission spectra using 
commercial purified NF-κB protein directly confirms 
cell-free binding interactions between platinum 
complex and NF-κB protein (Figure S9 and S10).  
 
 
Figure 3. (A) Untreated HELF or HepG2 cells stained with OsO4. (B,C) HELF or HepG2 cells treated with Pt complex (10 µM) for 30 min before processing for TEM. No other 
contrast stain was employed. (D) and (E) ICP-MS quantification of internalized Pt complex in nucleus and cytosol by HELF and HepG2 cells. Scale bars = 5 μm. 
 
 
Figure 4. (A) Co-localization studies of Pt complex (10 µM, 30 min) with NF-κB protein in HepG2 cells. NF-κB protein localization determined by immunofluorescence and 
Cy3-labelled secondary antibodies. (B) Co-localization of Pt complex with NF-κB protein in LPS untreated/treated RAW264.7 cells. (C) The Pearson’s correlation coefficient of 
Pt complex and Cy3 marked NF-κB protein. Scale bars = 20 μm. 
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Identification of normal and cancer cells in a 
metastases model 
Brain metastases originating from liver, lung or 
other types of cancer represent a substantial threat to 
life [37,38]. Since the interaction between Pt complex 
and NF-κB protein was confirmed, we were therefore 
motivated to explore this concept in a multi-culture 
environment. Cancer liver HepG2 cells and normal 
parenchymal Astrocytes cells (cell number ratio 1:10) 
were co-cultured and distributed randomly in a single 
well plate to mimic a simple brain metastases model. 
In order to identify the difference between cancer cells 
and normal cells under confocal microscopy, the 
parenchymal astrocytes was immunofluorescently 
stained with GFAP (glial fibrillary acidic protein, 2nd 
ab: Cy5, λex = 633 nm, λem = 640-680 nm) while all cells 
were indicated by DAPI (4',6-diamidino-2- 
phenylindole). Using this method, two distinct 
populations was observed; positive GFAP staining 
showing normal astrocytes while regions of negative 
GFAP staining but with positive DAPI signal indicate 
the HepG2 population (Figure 5A). This was 
converted to a two-colour sketch map (Figure 5B Red: 
normal cells; Green: cancer cells), where magnified 
macrophages from red and green region clearly 
displayed normal cell and cancer cell morphology 
with differentiated Pt complex distribution pattern 
(Figure 5C and 5D). Notably, the cancer cells that 
could be distinguished displayed intense Pt complex 
signal that overlapped with DAPI originating from 
the nucleus (Figure 5E and 5F). This is consistent with 
previous results and support the concept that Pt 
complex can highjack NF-κB protein and accumulate 
within cancer cell nuclei, while remaining deactivated 
form within the cytosolic region in normal cells. 
The cytotoxicity of Pt complex towards cancer 
cells and normal cells 
Considering the identified capability of Pt 
complex to target the nucleus of cancer – but not 
normal - cells, we measured its cytotoxicity by MTT 
method. HELF and HepG2 cells were chosen as 
normal and cancer cells, respectively. As shown in 
Figure 6A, B, Pt complex displayed high toxicity to 
HepG2 cells (IC50 = 0.28 µM) after 48 h incubation. 
Significantly reduced cytotoxicity towards normal 
HELF cells was observed, with negligible impact on 
 
 
Figure 5. (A) Confocal imaging of co-cultured normal cells (HepG2 cells) and cancer cells (Astrocytes cells): DAPI (Blue), GFAP (Red), Pt complex (Green), and Merge channel. 
(B) Schematic representation of normal cells and cancer cells population distribution from captured micrograph. (C) GFAP negative cells represent cancer cells with intense 
nuclear uptake. (D) GFAP positive astrocytes displayed cytosolic uptake without nuclear staining. (E) A zoom in micrograph showed Pt complex different intracellular distribution 
in the co-culture model from 5 cells including 1 HepG2 cell and 4 astrocytes. (F) Pt complex fluorescence analysis at nuclear and cytosol from astrocytes and HepG2 cells. Scale 
bars = 20 μm. Abbreviations: G2: HepG2 cells; As: Astrocytes; N: nucleus. 
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cell viability observed even at high concentration (IC50 
>50 µM). In comparison, cisplatin presented a 
nine-fold lower toxicity (IC50 = 2.56 µM, Figure 6A) to 
HepG2cancer cells and higher toxicity (IC50 = 3.36 µM, 
Figure 6B) to normal cells than Pt complex. To 
examine the mechanism of cell death, levels of 
apoptosis in cancer and normal cells treated with Pt 
complex was examined employing Annexin V 
staining and flow cytometry analysis. These results 
indicated substantially higher levels of early and late 
apoptotic cells in HepG2 cancer cells than normal 
HELF cells (Figure 6C, S11, 12), consistent with the 
death of cancer cells caused by Pt complex 
induced-apoptosis with low impact towards normal 
cells. 
The UV-visible and emission spectra of Pt 
complex (Figure S13) were altered with the titration of 
DNA [39], indicating a form of reversible DNA 
binding. Meanwhile, comparing cells treated with or 
without DNA hydrolase, the emission intensity of Pt 
complex was stable (Figure S14). These results suggest 
that Pt complex can interact with DNA and operates 
by an altered anti-cancer pathway compared to 
cisplatin, which might be attributed to interference 
with intracellular NF-κB protein function or 
ligand-DNA interactions. However, determination of 
the precise mechanism of action would require 
further investigation. These results confirmed 
preferential activity of Pt complex towards cancer 
cells compared to normal cells and implied Pt 
complex might have lower side effects than cisplatin, 
thus offering the possibility to utilise the complex in 
vivo.  
Anticancer ability in mice model and less 
side-effect towards kidney 
As indicated above, the Pt complex could 
selectively damage cancer cell in vitro. An untested 
cell, 4T1 cells, was chosen as cancer cell model to 
further confirm anti-cancer ability of Pt complex in 
vivo. With high cytotoxicity to 4T1 cells (Figure S15) 
and excellent penetration in 3D cancer cells tumour 
spheroids (Figure S16-17), studies with mouse 
xenograft models were performed. The mouse with 
solid tumour planted (n=6, 4T1 cells, flank injection) 
was treated with PBS, cisplatin, or Pt complex, 
respectively (3 weeks). Figure 7A directly presented 
that cisplatin treated mice showed significant side 
effects and gross changes in the skin including hair 
loss and messy pelage hair revealing considerable 
body damage; side effects that were not found in the 
Pt complex treatment group. Hematoxylineosin (HE) 
staining of kidney tissue sections of treated animals 
showed the region of cortex reins clearly presented 
that cisplatin had substantial damage to glomeruli 
kidney including decreasing glomerular volume and 
necrotic cells (Figure 7B). Conversely, the morphology 
of glomerular was complete with slight inflammation 
in Pt complex group. It is also encouraging to note 
that with extended treatment time (11 days), the 
growth of tumours in the Pt complex group were 
significantly inhibited and to a greater extent than 
animals treated with the clinical agent (Figure 7C and 
7E). Furthermore, the body weight of the Pt complex 
group remained similar as for non-treated animal, 
while a decrease was observed as a result of cisplatin 
treatment (Figure 7D); findings consistent with 
reduced side-effects from Pt complex compared to 
cisplatin.  
Conclusion 
In summary, a novel Pt complex was designed 
and synthesized based on both theoretical and 
experimental methods, and cellular studies showed 
this complex to possess high anti-cancer activity with 
little effect on normal cells. The anti-cancer 
mechanism was that Pt complex could identify the 
cancer cells and normal cells by hijacking endogenous 
nuclear factor kappa B protein. More importantly, its 
high toxicity to cancer cells and low damage to 
healthy cells could also be applied in mouse model 
experiment. Due to its non-invasiveness against 
normal tissues, Pt complex could be used as a 
potential anti-cancer candidate with an improved 
therapeutic index and reduced safety concerns 
compared to cisplatin. 
 
 
Figure 6. The Cytotoxicity of Pt complex (black line) and cisplatin (red line) (0.25 – 50 µM) against HepG2 (A) and HELF (B) cell lines (48 h incubation time). (C) The apoptosis 
rate of HELF and HepG2 cells cultured with Pt complex, as determined by AnnexinV/PI staining and flow cytometry analysis (24 h incubation time). 
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Figure 7. (A) Gross morphology of mice after intratumoural injection with Pt complex and cisplatin (3 mg/kg Pt drug at 1st, 3rd, and 5th day) at 11th day. (B) H&E staining of mice 
kidney treated with PBS, Pt complex, and cisplatin, the red-star indicated the damaged kidney region (C) The tumour volumes of mice model (murine breast cancer model, 4T1 
cell) over 21 days (Injected doses: 20 µL for PBS, 3 mg/kg for cisplatin, 3 mg/kg for Pt complex. Injected on 1st, 3rd, and 5th day). (D) Mouse body weight over 21 days for animals 
treated as in (C). (E) Tumour growth inhibition rate with Pt complex or cisplatin treatment at 11 day for animals treated as in (C). 
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